BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes

JAMA

Volumn 275, Issue 24, 1996, Pages 1885-1892

  Lerman, Caryn ^a,g   Narod, Steven ^b   Schulman, Kevin ^a   Hughes, Chanita ^a   Gomez Caminero, Andres ^a   Bonney, George ^c   Gold, Karen ^a   Trock, Bruce ^a   Main, David ^a   Lynch, Jane ^d   Fulmore, Cecil ^a   Snyder, Carrie ^d   Lemon, Stephen J ^d   Conway, Theresa ^d   Tonin, Patricia ^e   Lenoir, Gilbert ^f   Lynch, Henry ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; DEPRESSION; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEALTH INSURANCE; HEALTH STATUS; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MEDICAL DECISION MAKING; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 15844404355     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.24.1885     Document Type: Article

References (43)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;66:66-71.
2. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 1993;52:678-701.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1 -mutation carriers. Lancet. 1994;343:692-695.
4. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA. 1995;273:577-585.
5. Lynch HT, Watson P, Conway TA, Lynch JF. Natural history and age at onset of hereditary breast cancer. Cancer. 1992;69:1404-1407.
6. Lynch HT, Watson P, Conway TA, et al. DNA screening for breast/ovarian cancer susceptibility based on linked markers: a family study. Arch Intern Med. 1993;153:1979-1987.
7. Chaliki H, Loader S, Levenkron JC, et al. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health. 1995; 85:1133-1135.
8. Lerman C, Daly M, Masny M, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 1994;12:843-850.
9. Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 1995;57:385-392.
10. Struewing JP, Lerman C, Kase RG, et al. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev. 1995;4:169-173.
11. Craufurd D, Dodge A, Kerzin-Storrar L, et al. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet. 1989;2:603-605.
12. Quaid KA, Morris M. Reluctance to undergo predictive testing: the case of Huntington's disease. Am J Med Genet. 1993;45:41-45.
13. Bekker H, Modell M, Denniss G, et al. Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ. 1993;306:14-16.
14. Tambor ES, Bernhardt BA, Chase GA, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet. 1994;55:626-637.
15. Evers-Kiebooms G, Swerts A, Van den Berghe H. The motivation of at risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin Genet. 1989;35: 29-40.
16. Kessler S, Field T, Worth L, Mosbarger H. Attitudes of persons at risk for Huntington's disease toward predictive testing. Am J Med Genet. 1987;26:259-270.
17. King M-C, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? what are the choices? JAMA 1993;269:1975-1980.
18. Billings PR, Kohn MA, Cuevas M, et al. Discrimination as a consequence of genetic testing. Am J Hum Genet. 1992;50:476-482.
19. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993;269:1970-1974.
20. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med. 1994;154:609-616.
21. Engel JF, Blackwell RD, Miniard PW. Consumer Behavior. 8th ed. Fort Worth, Tex: The Dryden Press; 1995.
22. Ajzen I, Fishbein M. Understanding Attitudes and Predicting Social Behavior. Englewood Cliffs, NJ: Prentice-Hall International Inc; 1980.
23. Wiggins S, Whyte P, Huggins M, et al. The psychological consequences of predictive testing for Huntington's disease. N Engl J Med. 1992;327: 1401-1405.
24. Bloch M, Adam S, Wiggins S, Huggins M, Hayden MR. Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992;42:499-507.
25. American Society of Human Genetics (ASHG) Ad Hoc Committee on Genetic Testing for Breast and Ovarian Cancer. Statement on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet. 1994;55:ii-iv.
26. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA. 1994;271:785.
27. Serova O, Montagna M, Torchard, et al. A high incidence of BRCAl mutations in20 breast-ovarian cancer families. Am J Hum Genet. 1996;58:51-52.
28. Feunteun J, Narod SA, Lynch HT, et al. A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet. 1993;52: 736-742.
29. Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet. 1995; 56:254-264.
30. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385-401.
31. Sherbourne CD, Stewart AL, Wells KB. Role functioning measures. In: Stewart AL.Ware JE, eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:206-219.
32. Sherbourne CD. Social functioning: sexual problems measures. In: Stewart AL,Ware JE,eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:194-204.
33. Bonney GE. Regressive logistic models for familial disease and other binary traits. Biometrics. 1986;42:611-625.
34. Bonney GE. Compound regressive models for family data. Hum Hered. 1992;42:28-41.
35. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
36. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stot Assoc. 1983;78:427-434.
37. Nelson N. Caution guides genetic testing for cancer susceptibility genes. J Natl Cancer Inst. 1995;88:70-72.
38. Office of Technology Assessment (OTA). Genetic Tests and Health Insurance: Results of a Survey. Washington, DC: US Government Printing Office; 1992. Office of Technology Assessment (OTA) publication OTA-BP-BA-98.
39. Lynch HT, Lynch J, Conway T, Severin M. Psychological aspects of monitoring high-risk women for breast cancer. Cancer. 1994;74:1184-1192.
40. NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research. Genetic Information and Health Insurance: Report of the Task Force on Genetic Information and Insurance. Washington, DC: US Dept of Health and Human Services, Public Health Service; May 10, 1993. NIH publication 93-3686.
41. Collins FS. BRCA1 - lots of mutations, lots of dilemmas. N Engl J Med. 1996;334:186-188.
42. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995;11:196-200.
43. Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996;334:143-149.